Groundbreaking Discovery: How the APOE4 Gene Affects Brain Health Before Alzheimer's Symptoms Emerge

A team of researchers in the United States has made a significant breakthrough in understanding Alzheimer's disease, observing how the APOE4 gene, a known genetic risk factor, impacts the brain long before the first signs of memory loss appear. This finding, published in the prestigious journal Nature Aging, reveals an early and crucial mechanism that could redefine prevention and treatment strategies for this devastating neurodegenerative disease.

The APOE4 Gene and Its Early Effects

The APOE4 gene is widely recognized as the most potent genetic risk factor for late-onset Alzheimer's disease. It is estimated that between 60% and 75% of individuals who develop Alzheimer's carry this gene, and approximately one in four people in the general population possess it, often unknowingly. This high prevalence underscores the urgency of understanding its biological mechanisms. Scientists at the Gladstone Institute discovered that individuals who inherit the APOE4 gene produce exaggerated amounts of a specific protein called Nell2. This overproduction does not wait for old age or the first memory lapses; changes in neuron size and activity begin to manifest from a young age, particularly affecting the hippocampus, a brain region vital for memory formation and storage.

The Crucial Role of the Nell2 Protein

The research detailed how the excess Nell2 protein is primarily responsible for the observed alterations. In the presence of APOE4, neurons in the hippocampus become smaller and exhibit excessive activity, a phenomenon initially observed in mice genetically engineered to carry the human APOE4 gene. Although the study was conducted in animal models, the clues strongly suggest that a similar process occurs in the human brain. This discovery is fundamental because, until now, the direct relationship between APOE4 and Nell2 had not been studied, even though previous work had already linked elevated Nell2 levels with impaired cognitive function in Alzheimer's patients.

Neuronal Hyperactivity: An Early Warning Sign

The team, led by Drs. Yadong Huang and Misha Zilberter, set out to investigate the brain events that precede the disease's progression. By analyzing the brain activity of young APOE4 mice, they detected that certain areas of the hippocampus showed remarkable hyperactivity, a pattern absent in animals without this gene. Dennis Tabuena, one of the study's authors, emphasized the importance of this finding by explaining that the intensity of this hyperactivity in young mice predicted poorer performance in memory and spatial orientation tests as the animals aged. This indicates that neuronal damage begins long before it is clinically evident and that progression differs significantly between gene variants: with APOE3, a less risky version, hyperactivity took much longer to appear.

Implications for Treatment and Future Research

One of the most promising revelations of the study is the reversibility of these effects. The researchers demonstrated that by using gene-editing techniques to lower Nell2 levels in the hippocampus of adult APOE4 mice, neuron size normalized, and brain activity stabilized. This recovery was not dependent on the animals' age, which opens a window of hope for the development of treatments that could be effective even after pathological changes have begun. Furthermore, the study clarified that the detrimental effect of the APOE4 gene resides intrinsically within the neurons themselves, rather than in supporting cells called astrocytes—a crucial detail for future research and the design of targeted therapies.

This finding represents a giant leap in understanding the early mechanisms of Alzheimer's. By identifying Nell2 as a key mediator of APOE4's effects, scientists have uncovered a new pathway for therapeutic intervention. The possibility of normalizing neuronal function by modulating Nell2 levels, even in adult stages, offers an exciting prospect for developing drugs or gene therapies that could prevent or delay the progression of Alzheimer's disease in millions of people worldwide.